Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX - Delayed Quote AUD

Zelira Therapeutics Limited (ZLD.AX)

Compare
0.4800
0.0000
(0.00%)
As of 1:34:44 PM GMT+11. Market Open.
Loading Chart for ZLD.AX
  • Previous Close 0.4800
  • Open 0.4800
  • Bid 0.4800 x --
  • Ask 0.5000 x --
  • Day's Range 0.4800 - 0.4800
  • 52 Week Range 0.2800 - 1.0900
  • Volume 23
  • Avg. Volume 2,309
  • Market Cap (intraday) 5.447M
  • Beta (5Y Monthly) 0.76
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4200
  • Earnings Date Feb 26, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

zeliratx.com

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: ZLD.AX

View More

Performance Overview: ZLD.AX

Trailing total returns as of 3/18/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] .

YTD Return

ZLD.AX
22.58%
S&P/ASX 200 [XJO]
3.62%

1-Year Return

ZLD.AX
30.43%
S&P/ASX 200 [XJO]
2.08%

3-Year Return

ZLD.AX
84.76%
S&P/ASX 200 [XJO]
7.80%

5-Year Return

ZLD.AX
90.54%
S&P/ASX 200 [XJO]
64.41%

Compare To: ZLD.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZLD.AX

View More

Valuation Measures

As of 3/17/2025
  • Market Cap

    5.45M

  • Enterprise Value

    11.71M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    133.22

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    286.45

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -92.11%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    40.88k

  • Net Income Avi to Common (ttm)

    -4.84M

  • Diluted EPS (ttm)

    -0.4200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    38.19k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.41M

Research Analysis: ZLD.AX

View More

People Also Watch